Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)

Phase 4TerminatedNCT00758342

Alcon Research37 enrolled

Overview

To evaluate the IOP (Intraocular Pressure) lowering efficacy and safety of Brinzolamide 1.0% (Azopt), dosed twice daily as adjunctive therapy in patients treated with Travoprost 0.004% (Travatan) once daily. The study is double masked. The patients will receive either treatment for 12 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Intraocular Pressure

Interventions

Travoprost 0.004% + Brinzolamide 1.0%DRUG

Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)

Travoprost 0.004% + Tears NaturalDRUG

Travoprost 0.004% (once daily) + Tears Naturale (twice daily)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ≥ 18 years; * CACG (Chronic Angle Closure Glaucoma) ≥ 1eye * have been treated with PGA (prostaglandin analogues) once daily ≥ 2 weeks prior to the screening visit and IOP=19-32 mmHg (millimeters mercury) in at least one eye and ≤ 32 mmHg in both eyes * clinical stability of VA (Visual Acuity) and optic nerve throughout the study Exclusion Criteria: * Abnormality restricts exam of the fundus or anderior chamber * conjunctivitis, keratitis or uveitis * unable to be discontinued from using all ocular hypotensive medication(s) except Travatan (Travoprost 0.004%) and/or Azopt (Brinzolamide 1.0%) for 12days-4weeks * ocular surgery prior to the study

Outcomes

Primary Outcomes

Mean IOP (Intraocular Pressure)

Time frame: Screening: Week 12; (At 9 am and 4 pm time points)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.